JP2019527208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527208A5 JP2019527208A5 JP2018568785A JP2018568785A JP2019527208A5 JP 2019527208 A5 JP2019527208 A5 JP 2019527208A5 JP 2018568785 A JP2018568785 A JP 2018568785A JP 2018568785 A JP2018568785 A JP 2018568785A JP 2019527208 A5 JP2019527208 A5 JP 2019527208A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- delivery device
- polymer
- pharmaceutically active
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 40
- 229940079593 drug Drugs 0.000 claims description 39
- 239000003557 cannabinoid Substances 0.000 claims description 34
- 229930003827 cannabinoid Natural products 0.000 claims description 34
- 229920000642 polymer Polymers 0.000 claims description 30
- 238000012377 drug delivery Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 230000002496 gastric effect Effects 0.000 claims description 19
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 17
- 229940065144 cannabinoids Drugs 0.000 claims description 13
- 230000014759 maintenance of location Effects 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 6
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000010410 layer Substances 0.000 claims 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 9
- 239000004014 plasticizer Substances 0.000 claims 8
- 229920001223 polyethylene glycol Polymers 0.000 claims 8
- 241000218236 Cannabis Species 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 239000002775 capsule Substances 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- -1 citrate ester Chemical class 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 5
- 239000000194 fatty acid Substances 0.000 claims 5
- 229930195729 fatty acid Natural products 0.000 claims 5
- 150000004665 fatty acids Chemical class 0.000 claims 5
- 239000004359 castor oil Substances 0.000 claims 4
- 235000019438 castor oil Nutrition 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002191 fatty alcohols Chemical class 0.000 claims 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical group O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 3
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 3
- 235000011187 glycerol Nutrition 0.000 claims 3
- 125000005908 glyceryl ester group Chemical group 0.000 claims 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 3
- 229920001983 poloxamer Polymers 0.000 claims 3
- 229920000136 polysorbate Polymers 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 239000012790 adhesive layer Substances 0.000 claims 2
- 230000000181 anti-adherent effect Effects 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 229960001777 castor oil Drugs 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims 2
- 210000004051 gastric juice Anatomy 0.000 claims 2
- 229940075529 glyceryl stearate Drugs 0.000 claims 2
- 239000001087 glyceryl triacetate Substances 0.000 claims 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 2
- 230000002650 habitual effect Effects 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 2
- 235000019198 oils Nutrition 0.000 claims 2
- 239000004006 olive oil Substances 0.000 claims 2
- 235000008390 olive oil Nutrition 0.000 claims 2
- 229960000502 poloxamer Drugs 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229960002622 triacetin Drugs 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 235000021357 Behenic acid Nutrition 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000014997 Crohn colitis Diseases 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 claims 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 claims 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 claims 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims 1
- 229920002571 Polyethylene Glycol 4500 Polymers 0.000 claims 1
- 229920002575 Polyethylene Glycol 540 Polymers 0.000 claims 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 claims 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229940075534 amino methacrylate copolymer Drugs 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 229940116226 behenic acid Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229920001531 copovidone Polymers 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 229960005168 croscarmellose Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229940031954 dibutyl sebacate Drugs 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 229920000578 graft copolymer Polymers 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims 1
- 229940068965 polysorbates Drugs 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 229920003169 water-soluble polymer Polymers 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360744P | 2016-07-11 | 2016-07-11 | |
| US62/360,744 | 2016-07-11 | ||
| PCT/IL2017/050783 WO2018011798A1 (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019527208A JP2019527208A (ja) | 2019-09-26 |
| JP2019527208A5 true JP2019527208A5 (cg-RX-API-DMAC10.html) | 2020-08-20 |
Family
ID=59388117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568785A Pending JP2019527208A (ja) | 2016-07-11 | 2017-07-11 | 経口胃保持製剤及びその使用 |
Country Status (17)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018152334A1 (en) * | 2017-02-15 | 2018-08-23 | Molecular Infusions, Llc | Formulations |
| BR102018002843A2 (pt) * | 2018-02-09 | 2019-08-27 | Prati, Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
| WO2020037410A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with enhanced cannabinoid profile user experience |
| GB2584341B (en) * | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| CN114650809A (zh) | 2019-10-03 | 2022-06-21 | 斯塔顿治疗公司 | 屈大麻酚的透皮递送 |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12186280B2 (en) | 2019-10-11 | 2025-01-07 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| JP2022551730A (ja) | 2019-10-14 | 2022-12-13 | パイク セラピューティクス，インコーポレイテッド | カンナビジオールの経皮送達 |
| US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
| EP4084790A1 (en) * | 2020-01-02 | 2022-11-09 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Floating drug delivery systems comprising cannabinoids |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023272335A1 (en) * | 2021-06-30 | 2023-01-05 | Emyria | Cannabidiol formulation comprising a matrix pellet forming excipient |
| CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
| TW202430130A (zh) * | 2022-10-18 | 2024-08-01 | 大陸商南京三迭紀醫藥科技有限公司 | 用於胃滯留的口服藥物劑型 |
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03163011A (ja) * | 1989-08-31 | 1991-07-15 | Yamanouchi Pharmaceut Co Ltd | 胃内滞留デバイス |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| US9265724B2 (en) * | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| PT1903866E (pt) | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| DK2997953T3 (en) | 2006-01-18 | 2019-04-15 | Intec Pharma Ltd | ADMINISTRATION ORAL ADMINISTRATION |
| DK2276473T3 (en) * | 2008-04-18 | 2017-01-09 | Intec Pharma Ltd | GASTRORETENTIV drug TO carbidopa / levodopa |
| WO2010064139A2 (en) * | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Zaleplon gastroretentive drug delivery system |
| WO2011048494A2 (en) | 2009-10-19 | 2011-04-28 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| US20140017303A1 (en) * | 2010-11-01 | 2014-01-16 | Intec Pharma Ltd. | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
| US8808734B2 (en) | 2011-07-11 | 2014-08-19 | Full Spectrum Laboratories Limited | Cannabinoid formulations |
| KR20160002709A (ko) * | 2013-02-12 | 2016-01-08 | 코버스 파마수티컬스, 아이엔씨. | 초고순도 테트라하이드로카나비놀-11-오익산 |
| WO2015025312A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
-
2017
- 2017-07-11 RU RU2019103297A patent/RU2019103297A/ru not_active Application Discontinuation
- 2017-07-11 NZ NZ750422A patent/NZ750422A/en unknown
- 2017-07-11 AU AU2017296351A patent/AU2017296351A1/en not_active Abandoned
- 2017-07-11 KR KR1020197002888A patent/KR20190026799A/ko not_active Ceased
- 2017-07-11 CN CN201780041708.3A patent/CN109414403A/zh active Pending
- 2017-07-11 JP JP2018568785A patent/JP2019527208A/ja active Pending
- 2017-07-11 WO PCT/IL2017/050783 patent/WO2018011798A1/en not_active Ceased
- 2017-07-11 CA CA3027700A patent/CA3027700A1/en not_active Abandoned
- 2017-07-11 MX MX2019000348A patent/MX2019000348A/es unknown
- 2017-07-11 SG SG10202100182TA patent/SG10202100182TA/en unknown
- 2017-07-11 EP EP17743090.7A patent/EP3481371A1/en not_active Withdrawn
- 2017-07-11 US US16/316,390 patent/US20190224118A1/en not_active Abandoned
- 2017-07-11 BR BR112018077541-0A patent/BR112018077541A2/pt not_active Application Discontinuation
- 2017-07-11 SG SG11201811209QA patent/SG11201811209QA/en unknown
-
2019
- 2019-01-02 IL IL264065A patent/IL264065A/en unknown
- 2019-01-09 PH PH12019500061A patent/PH12019500061A1/en unknown
- 2019-01-15 ZA ZA2019/00275A patent/ZA201900275B/en unknown
- 2019-01-23 CO CONC2019/0000643A patent/CO2019000643A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250177320A1 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| US9980902B2 (en) | Method for treating intestinal fibrosis | |
| US9693981B2 (en) | Zaleplon gastroretentive drug delivery system | |
| JP6434429B2 (ja) | デフェラシロクスの経口製剤 | |
| RU2019103297A (ru) | Гастроретентивные составы для перорального введения и пути их применения | |
| RU2744576C2 (ru) | Пероральные фармацевтические композиции месалазина | |
| BRPI0809563A2 (pt) | Formas de dosagem modificadas de tacrolimus | |
| US20170119680A1 (en) | Extended release film-coated capsules | |
| RU2010109408A (ru) | Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия | |
| RU2577164C2 (ru) | Таблетки с регулируемым по месту и времени высвобождением глюкокортикоида в желудочно-кишечном тракте | |
| JP2021152050A (ja) | フマル酸ジメチルを含む医薬ビーズ製剤 | |
| RU2738114C2 (ru) | Пероральные фармацевтические композиции никотинамида | |
| CN116322657A (zh) | 包括氘代丁苯那嗪的多颗粒剂型 | |
| US20180161281A1 (en) | Extended release pharmaceutical composition of mixed amphetamines | |
| HK40111914A (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
| CN118103032A (zh) | 包括氘代丁苯那嗪的多微粒剂型 | |
| US20210113479A1 (en) | Dosage forms for delivery of medicines to the lower gastrointestinal tract | |
| CN121240855A (zh) | 用于脉冲释放的药物剂型 | |
| HK40093967A (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
| EA046180B1 (ru) | Фармацевтический состав флороглюцинола и триметилфлороглюцинола | |
| HK40012399A (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
| HK40012399B (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol |